Absci to Participate in the Guggenheim Securities SMID Cap Biotech Conference
Absci (Nasdaq: ABSI), a data-first generative AI drug creation company, has announced its participation in the upcoming Guggenheim Securities SMID Cap Biotech Conference in New York. The company's management will engage in a fireside chat on Wednesday, February 5th at 3:00 p.m. Eastern Time (12:00 p.m. Pacific Time). Interested investors and stakeholders can access both live and archived webcasts of the presentation through Absci's investor relations website at investors.absci.com.
Absci (Nasdaq: ABSI), un'azienda di creazione di farmaci generativi basata sui dati, ha annunciato la sua partecipazione alla prossima Conferenza Biotech SMID Cap di Guggenheim Securities a New York. Il management dell'azienda parteciperà a una chat informale il mercoledì 5 febbraio alle 15:00 ora orientale (12:00 ora pacifica). Gli investitori e gli interessati possono accedere sia alle trasmissioni in diretta che a quelle registrate della presentazione tramite il sito web delle relazioni con gli investitori di Absci all'indirizzo investors.absci.com.
Absci (Nasdaq: ABSI), una empresa de creación de fármacos generativos basada en datos, ha anunciado su participación en la próxima Conferencia Biotech SMID Cap de Guggenheim Securities en Nueva York. La dirección de la empresa participará en una charla informal el miércoles 5 de febrero a las 3:00 p.m. hora del Este (12:00 p.m. hora del Pacífico). Los inversores y partes interesadas pueden acceder tanto a las transmisiones en vivo como a las grabadas de la presentación a través del sitio web de relaciones con inversores de Absci en investors.absci.com.
Absci (Nasdaq: ABSI)는 데이터 기반의 생성 AI 약물 개발 회사로, 뉴욕에서 열리는 구겐하임 증권 SMID 캡 생명공학 회의에 참석한다고 발표했습니다. 회사 경영진은 2월 5일 수요일 오후 3시 동부 표준시 (오후 12시 태평양 표준시)에 화상 대화에 참여할 것입니다. 관심 있는 투자자와 이해관계자는 Absci의 투자자 관계 웹사이트인 investors.absci.com을 통해 발표의 라이브 및 아카이브 웹캐스트를 모두 이용할 수 있습니다.
Absci (Nasdaq: ABSI), une entreprise de création de médicaments générative basée sur les données, a annoncé sa participation à la prochaine Conférence Biotech SMID Cap de Guggenheim Securities à New York. La direction de l'entreprise participera à une discussion informelle le mercredi 5 février à 15h00 heure de l'Est (12h00 heure du Pacifique). Les investisseurs et parties prenantes intéressés peuvent accéder aux webcasts en direct et archivés de la présentation sur le site web des relations avec les investisseurs d'Absci à l'adresse investors.absci.com.
Absci (Nasdaq: ABSI), ein datenbasierter Anbieter für die Generierung von KI-gestützten Arzneimitteln, hat seine Teilnahme an der bevorstehenden Guggenheim Securities SMID Cap Biotech Konferenz in New York angekündigt. Das Management des Unternehmens wird am Mittwoch, den 5. Februar um 15:00 Uhr Eastern Time (12:00 Uhr Pacific Time) an einem informellen Gespräch teilnehmen. Interessierte Investoren und Beteiligte können sowohl auf die Live- als auch auf die aufgezeichneten Webcasts der Präsentation über Absci's Investor Relations-Website unter investors.absci.com zugreifen.
- None.
- None.
VANCOUVER, Wash. and NEW YORK, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will be participating in the upcoming Guggenheim Securities SMID Cap Biotech Conference in New York, NY.
Absci management is scheduled to participate in a fireside chat on Wednesday, February 5th at 3:00 p.m. Eastern Time (12:00 p.m. Pacific Time). Interested parties may access a live and archived webcast on the company’s investor relations website at: investors.absci.com.
About Absci
Absci is a data-first generative AI drug creation company that combines AI with scalable wet lab technologies to create better biologics for patients, faster. Our Integrated Drug Creation™ platform unlocks the potential to accelerate time to clinic and increase the probability of success by simultaneously optimizing multiple drug characteristics important to both development and therapeutic benefit. With the data to train, the AI to create, and the wet lab to validate, we can screen billions of cells per week, allowing us to go from AI-designed candidates to wet lab-validated candidates in as little as six weeks. Absci’s headquarters is in Vancouver, WA, with our AI Research Lab in New York City and an Innovation Center in Zug, Switzerland. Visit www.absci.com and follow us on LinkedIn (@absci), X (Twitter) (@Abscibio), and YouTube.
Investor Contact
Alex Khan
VP, Finance & Investor Relations
investors@absci.com
Media Contact
press@absci.com
FAQ
When is Absci (ABSI) presenting at the Guggenheim SMID Cap Biotech Conference 2025?
How can investors watch Absci's (ABSI) Guggenheim Conference presentation?
What type of presentation will Absci (ABSI) give at the Guggenheim Biotech Conference?
Where is the Guggenheim SMID Cap Biotech Conference featuring Absci (ABSI) being held?
